# US 6,726,931 B2 · Process for preparing oral sustained-release formulation of felodipine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,726,931 B2
- Document ID: US6726931B2
- Status: Granted
- Kind: B2
- Application number: 10/118,690
- Filed: 2002-04-08
- Published: 2003-10-09
- Granted: 2004-04-27
- Earliest claimed: 2002-04-08
- Assignees: Standard Chem. & Pharm. Co., Ltd.
- Inventors: Yea-Sheng Yang; Ya-Ching Changchien
- Web page: https://patentgrep.com/patent/US6726931B2

## CPC

- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a process for producing an oral sustained-release pharmaceutical composition of felodipine. The process includes mixing together felodipine with at least an ionic surfactant or hydrophilic polymer, and at least a release-controlling excipient. The pharmaceutical composition of felodipine produced by the process of the present invention possesses the enhanced dissolution rate of the insoluble drug of felodipine, whereas the sustained releasing profile and superior bioavailability of the produced pharmaceutical composition of felodipine are retained.

## Claims

### Claim 1

A process for preparing an oral sustained-release formulation of felodipine, comprising mixing felodipine, at least an ionic surfactant or hydrophilic polymer and at least a release-controlling excipient to form a uniform felodipine mixture in one step,
wherein the release-controlling excipient is selected from hydrophilic colloid, hydrophobic cellulose and wax.

### Claim 2 (depends on 1)

The process as claimed in claim 1, comprising mixing felodipine with at least an ionic surfactant and at least a release controlling excipient to form a uniform mixture in one step.

### Claim 3 (depends on 2)

The process as claimed in claim 2, wherein the ionic surfactant is sodium dioctylsulfonyl succinate or sodium lauryl sulfate.

### Claim 4 (depends on 1)

The process as claimed in claim 1, wherein the hydrophilic polymer is polyvinyl pyrrolidone (Pvp), hydroxyethyl cellulose (HEC), hydroxy propyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC) or polyvinyl alcohol (PVA).

### Claim 5 (depends on 1)

The process as claimed in claim 1, wherein the release controlling excipient is gelatin, shellac, hydroxypropylmethyl cellulose (HPMC), methylcellulose (MC), ethylcellulose (EC), hydroxypropylmethyl cellulose phthalate (HPMCP), cellulose phthalate acetate (APC), methacrylic acid/methyl methacrylate copolymers, polyvinyl acetate phthalate (PVAP), glyceryl behenate, paraffin or carnauba wax.

### Claim 6 (depends on 1)

The process as claimed in claim 1, which further comprises further adding a diluent in the step to form the felodipine mixture.

### Claim 7 (depends on 6)

The process as claimed in claim 6, wherein the diluent is microcrystalline cellulose, starch, lactose, silicon dioxide, calcium biphosphate, calcium phosphate, calcium carbonate, magnesium carbonate, aluminum silicate, magnesium silicate or mannitol.

### Claim 8 (depends on 6)

The process as claimed in claim 6, wherein the diluent is microcrystalline cellulose, lactose, silicon dioxide or calcium biphosphate.

### Claim 9 (depends on 6)

The process as claimed in claim 6, which further comprises adding a lubricant in the step to form the felodipine mixture.

### Claim 10 (depends on 9)

The process as claimed in claim 9, wherein the lubricant is talc powder, stearic acid, stearyl acetate, sodium stearyl fumarate or glyceryl behenate.

### Claim 11 (depends on 1)

The process as claimed in claim 1, which further comprises compressing the felodipine mixture into tablets.

### Claim 12 (depends on 6)

The process as claimed in claim 6, which further comprises compressing the felodipine mixture into tablets.

### Claim 13 (depends on 9)

The process as claimed in claim 9, which further comprises compressing the felodipine mixture into tablets.

### Claim 14 (depends on 1)

The process as claimed in claim 1, which further comprises encapsulating the felodipine mixture.

### Claim 15 (depends on 6)

The process as claimed in claim 6, which further comprises encapsulating the felodipine mixture.

### Claim 16 (depends on 9)

The process as claimed in claim 9, which further comprises encapsulating the felodipine mixture.

### Claim 17 (depends on 1)

The process as claimed in claim 1, which further comprises:
mixing the felodipine mixture with water or an organic solvent, and
granulating the resultant mixture into granules by a wet-granulation method.

### Claim 18 (depends on 17)

The process as claimed in claim 17, which further comprises drying the granules followed by compressing the dried granules into tablets.

### Claim 19 (depends on 17)

The process as claimed in claim 17, which further comprises drying the granules followed by encapsulating the dried granules.

### Claim 20 (depends on 18)

The process as claimed in claim 18, which further comprising coating the tablets with a light-resisting film.

### Claim 21 (depends on 17)

The process as claimed in claim 17, wherein the solvent is alcohol, acetone, isopropanol, dichloromethane or other dissolvable media.

### Claim 22 (depends on 20)

The process as claimed in claim 20, wherein the light resisting film is made of material selected from the group consisting of hydroxypropylmethyl cellulose, polyethylene glycol, titanium dioxide and ferrous oxide.

### Claim 23 (depends on 17)

The process as claimed in claim 17, wherein the granules are dried until a water-containing ratio of 0.4% to 6% (w/w) of the granules is attained.
